Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
Carfilzomib, proteasome inhibitor; intravenous
Filanesib, KSP(Eg5) inhibitor; intravenous
+2 more
Locations
22
United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
UCLA
Los Angeles, California, United States
St. Joseph Heritage Healthcare
Santa Rosa, California, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States
Crescent City Research Consortium
Marrero, Louisiana, United States
Start Date
November 1, 2013
Primary Completion Date
February 1, 2016
Completion Date
May 1, 2016
Last Updated
September 16, 2020
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions